Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-05-15
2007-05-15
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S210160, C514S252120, C514S570000, C514S323000, C514S367000
Reexamination Certificate
active
10786810
ABSTRACT:
The present invention relates to the combination of one or more CB1 antagonist azetidine derivatives and of one or more products which activate dopaminergic neurotransmission in the brain, to the pharmaceutical compositions comprising them and to their use in the treatment of Parkinson's disease.
REFERENCES:
patent: 5562917 (1996-10-01), Durif et al.
patent: 6355631 (2002-03-01), Achard et al.
Brotchie, J. M., The Cannabinoid Receptor Antagonist SR141716A Reduces L-DOPA- Induced Dyskinesia in the MPTP-Treated Primate Model of Parkinson's Disease, British Journal of Pharmacology (1998, vol. 123, pp. 66P).
Clara Sanudo-Pena et al., A Novel Neurotransmitter System Involved in the Control of Motor Behavior by the Basal Ganglia, Ann. New York Academy of Sciences, (1998, vol. 860, pp. 475-479).
Justin P. Meschler et al., D2, but not D1 Dopamine Receptor Agonists Potentiate Cannabinoid-Induced Sedation In Nonhuman Primates 1,2 Journal of Pharmacology And Experimental Therapeutics, (2000, vol. 292, Issue 3, pp. 952-959).
Vincenzo Di Marzo et al., Enhanced Levels of Endogenous Cannabinoids in the Globus Pallidus are Associated with a Reduction in Movement in an animal model of Parkinson's Disease, FASEB Journal (2000, vol. 14, Issue 10, pp. 1432-1438).
Benavides Jesus
Boccio Daniel
Henin Yvette
Piot-Grosjean Odile
Aventis Pharma S.A.
Chong Yong S.
Gupta Balaram
Padmanabhan Sreeni
LandOfFree
Combination of a CB1 receptor antagonist and of a product... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of a CB1 receptor antagonist and of a product..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of a CB1 receptor antagonist and of a product... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3777161